Restless legs syndrome in pregnancy

A meta-analysis pooling 27 studies and 51,717 pregnant women found restless legs syndrome in about 1 in 5 pregnancies overall (21%) — and the rate climbs as pregnancy progresses: roughly 8% in the first trimester, 16% in the second, and 22% in the third, before falling to about 4% within weeks of delivery.

A large, more recent prospective cohort (the Life-ON study, 439 women followed from early pregnancy to one year postpartum) found a similar 26% prevalence across at least one antenatal visit, with a cumulative incidence of 34.7% by 12 months after birth — a reminder that pregnancy-related restless legs syndrome does not always resolve as quickly or completely as the trimester numbers on their own suggest.

The leading explanation is timing: pregnancy sharply increases the body's iron demand — for the expanding blood volume and for the fetus and placenta — right when restless legs syndrome symptoms peak, in the third trimester. Lower hemoglobin and less iron or vitamin supplementation have tracked with restless legs syndrome in more than one pregnancy study.

A role for rising pregnancy hormones, estrogen especially, has also been proposed, but the human evidence is genuinely mixed, not settled. One small study of 19 women found significantly higher third-trimester estradiol in women with restless legs syndrome than in unaffected pregnant women. A separate, larger study of 146 women measuring the same hormone panel found no significant estradiol difference at all, and instead found lower hemoglobin and less iron supplementation as the factors that actually distinguished the two groups. Neither study is large by modern standards, and an adequately powered study has not resolved the question either way.

Because pregnancy limits which medications can be used, non-drug measures are the sensible starting point — and a few of them have actual randomized-trial support in pregnant women specifically, not only in the general restless legs syndrome population.

An International Restless Legs Syndrome Study Group (IRLSSG) task force of restless legs syndrome and obstetric experts published consensus guidelines for pregnancy and lactation. Non-pharmacologic measures — reassurance, exercise, avoiding known symptom triggers — come first; iron supplementation is treated as a core, foundational intervention; and medication is rated for pregnancy and lactation risk versus benefit, with only a few options described as "may be considered," and only once conservative measures have not been enough.

A later clinical review reached the same structure: non-drug measures first, oral iron when ferritin is low, and pharmacologic options reserved for refractory or severe symptoms — because the pregnancy- and lactation-specific safety evidence for most restless legs syndrome medications remains limited.

Iron-status testing — ferritin, and often transferrin saturation — is the foundational, physician-ordered step guidelines recommend before anything else. The same underlying biology behind the ferritin thresholds used outside pregnancy applies here too, but the actual testing schedule and iron dosing decisions in pregnancy are your physician's call, never a self-directed one.

When iron deficiency persists in pregnancy despite oral iron, IV iron works better: in a randomized trial of 201 pregnant women with persistent iron deficiency, a single IV iron infusion kept significantly more women out of anemia over 18 weeks than continuing oral iron (91% versus 73%), with greater hemoglobin gains and better fatigue and quality-of-life scores. That trial measured anemia and quality of life, not restless legs syndrome symptoms directly — worth stating plainly rather than implying it is restless-legs-specific evidence.

Guideline literature treats both major restless legs syndrome drug classes — dopamine agonists such as pramipexole, and alpha-2-delta ligands such as gabapentin — with particular caution in pregnancy, because teratogenicity and lactation-transfer data for both classes remain limited. That is a reason for extra caution and physician involvement, not something this page can resolve for you individually.

The best available pregnancy-specific safety data covers gabapentin: pooling 294 first-trimester gabapentin exposures across five pregnancy registries found a major-malformation rate of 1.7%, comparable to the 1.6–2.2% background rate in the general population. That is a cautiously reassuring signal, not a guarantee — it comes from pooled registries, not a randomized trial, and the numbers are still small for detecting rarer effects.

One rule never changes for pregnancy: a dopamine agonist is never stopped or reduced abruptly. Augmentation and dopamine-agonist withdrawal syndrome are real risks of mishandled tapering, and pregnancy does not remove that risk — any change to an existing medication is planned with your prescriber, never made on your own.

For most, symptoms ease quickly: the same 27-study meta-analysis found prevalence falling from about 22% in the third trimester to roughly 4% within weeks of delivery. But "usually gets better" is not "always resolved" — the Life-ON cohort found cumulative incidence continued climbing to 34.7% by 12 months postpartum, meaning a meaningful share of women were still affected well beyond the immediate postpartum window.

Pregnancy-onset restless legs syndrome also has a longer shadow: a review of the evidence found that women whose restless legs syndrome first appeared during pregnancy face a higher risk of it recurring in future pregnancies, and a higher risk of developing chronic restless legs syndrome later in life, than women who never had pregnancy-related symptoms. Neither fact is a reason for alarm — most people do improve — but they are worth knowing rather than assuming pregnancy is always a one-time, fully self-limited episode.

If restless legs syndrome symptoms are still disruptive weeks after delivery, keep recurring in later pregnancies, or settle into a longer-term pattern, that is a reasonable point to involve a neurologist or sleep-medicine physician rather than continuing to manage it alone. The evidence-graded, physician-supervised long-term plan on this site — iron repletion, removing aggravating drugs, and a careful medication approach when needed — applies just as much once pregnancy is no longer the driver.

A primary-care physician or your obstetric provider can start the initial workup (ferritin and transferrin saturation); a specialist referral is the natural next step if symptoms are severe, persistent, or medication is being considered.